Prometheus Biosciences, Inc. (RXDX) Financial Analysis & Valuation | Quarter Chart
Prometheus Biosciences, Inc. (RXDX)
RXDXPrice: $199.92
Fair Value: 🔒
🔒score
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antib... more
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, an... more
Description
Shares
| Market Cap | $9.56B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Mark C. McKenna |
| IPO Date | 2021-03-12 | CAGR | 0.61% |
| Employees | 97 | Website | www.prometheusbiosciences.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.01% | Total Yield | -0.01% |
RXDX chart loading...
Fundamentals
Technicals
| Enterprise Value | $5.01B | P/E Ratio | -56.47 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 1403.81 | P/B Ratio | 12.01 |
| P/CF Ratio | -65.88 | P/FCF Ratio | -75.89 |
| EPS | $-3.54 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -36.47% | Gross Margin | 1% |
| Operating Margin | -21.41% | Profit Margin | -20.82% |
| ROE | -0.31% | ROA | -0.19% |
| ROCE | -0.2% | Current Ratio | 31.04 |
| Quick Ratio | 31.08 | Cash Ratio | 12.82 |
| Debt/Equity | 0.04 | Interest Coverage | — |
| Altman Z Score | 94.07 | Piotroski Score | 2 |